ArticleEuropean urology2025

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].

Kelly N Fitzgerald et al.PubMed ↗Publisher ↗

No numbers read from the abstract.